Diagnostic Value of TROP2 Expression in Papillary Thyroid Carcinoma

Saffar, Hiva; Jahanbin, Behnaz; Ameli, Fereshteh; Farhang, Fatemeh; Tavangar, Seyed Mohammad

doi:10.1097/pai.0000000000000886

Cited by 5 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study showed positive membranous TROP-2 expression in 97.1% of PTC cases (34 out of 35). These results were consistent with the research conducted by Yang et al [ 1 ], Zargari et al [ 21 ], and Saffer et al [ 23 ]. TROP-2 positivity was 96%, 93%, and 98% in them, respectively.…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Diagnostic and prognostic utility of TROP-2, SLP-2, and CXCL12 expression in papillary thyroid carcinoma

Attia,

Hussein,

Sameh

et al. 2024

CBM

View full text Add to dashboard Cite

BACKGROUND: Papillary thyroid carcinoma (PTC) is the most frequent thyroid malignancy. Histopathological examination is widely accepted as the gold standard test for the diagnosis of PTC. However, the histopathological examination sometimes can’t differentiate PTC from other thyroid diseases. Differentiating PTC from other thyroid diseases is essential for a therapeutic approach and prognosis. OBJECTIVES: The current study was performed to investigate the utility of TROP-2, SPL-2, and CXCL12 mRNA and protein expression in discriminating PTC from other thyroid diseases that mimic PTC. METHODS: The current study was performed on 75 cases of surgically resected thyroid glands. The cases were distributed in two groups: the PTC group and the non-PTC group. The PTC group consisted of 35 cases (25 patients of the classic PTC variant and 10 patients of the PTC follicular variant). The non-PTC group consisted of 40 cases (10 cases were multinodular goiter, 5 cases were Graves’ disease, 5 cases were Hashimoto thyroiditis, 15 patients were follicular adenoma (FA) and 5 cases were follicular carcinoma). TROP-2, SPL-2, and CXCL12 mRNA expression were estimated by qRT-PCR, and protein expression was estimated by immunohistochemistry. RESULTS: There were upregulated TROP-2, SPL-2, and CXCL12 mRNA and protein expressions in PTC compared to non-PTC (P< 0.001, for each). There was a statistically significant upregulation in the mRNA expression of the three genes among PTC cases with larger tumor sizes (P< 0.001, for each), those with tumor stages III and IV (P= 0.008, 0.002 and < 0.001 respectively), and those with LN metastasis (P< 0.001, for each). Moreover, there was a statistically significant upregulation in CXCL-12 gene expression among PTC cases with extra-thyroid extension (P< 0.001). CONCLUSION: mRNA expression of TROP-2, SPL-2, and CXCL12 among PTC cases increased in larger tumor size, tumor stages III and IV, and LN metastasis. Moreover, there was an increase in CXCL-12 gene expression among PTC cases with extra-thyroid extension. Thus, TROP-2, SPL-2, and CXCL12 expressions could be possible diagnostic and prognostic markers in PTC.

show abstract

Section: Discussionsupporting

confidence: 93%

“…The current study showed that there is a significant difference in TROP-2 positive expression between PTC cases and non-PTC cases. This result is compatible with Abdou et al [ 3 ], Addati et al [ 22 ], Saffer et al [ 23 ], Bychkov et al [ 8 ], and Lui et al [ 7 ] that reported that TROP-2 is a new marker in the diagnosis of PTC.…”

Section: Discussionsupporting

confidence: 91%

Diagnostic and prognostic utility of TROP-2, SLP-2, and CXCL12 expression in papillary thyroid carcinoma

Attia,

Hussein,

Sameh

et al. 2024

CBM

View full text Add to dashboard Cite

show abstract

“…In this study the immunohistochemical method was used to assess the TROP2 expression in PTC patients compares with healthy persons . The study results demonstrate that a significant value in TROP2 expression in PTC patients between PTC and control groups , that agree with SAFFAR ,et al 2021 (5) . The present study found that increase TROP2 expression in PTC group.…”

Section: Discussionsupporting

confidence: 90%

The Effect of TROP2 Expression on Papillary Thyroid Carcinoma Development in Iraqi Patients

Sadik A. Abdullah

2021

Indian Journal of Forensic Medicine & Toxicology

View full text Add to dashboard Cite

Background : Papillary Thyroid Carcinoma (PTC) is common type of the thyroid cancers, it's onset in female at 30-50 years more than male and account for about 80% of all thyroid cancer cases . PTC diagnosis depend on histo-pathological finds of abnormal papillary architectures in the tissue as golden standerd of PTC diagnosis . Trophoblast cell surface antigen 2 (TROP2) is trans-membrane glycoprotein receptor ,encoded by Tacstd2 gene , observe in various cancer types specially epithelial cancers . TROP2 has the up-regulation ( overexpression) in cancer cells such as pancreatic , thyroid and ovarian cancers. Objective of the Study:It's shown up-regulation of TROP 2 in PTC Iraqi patients by Immunohistochemical method. Materials and Methods:The current study done in Al-Yarmook Teaching Hospital from March 2020 to January 2021 , was included 30 cases of PTC patients and 30 healthy subjects , all of subject's age were more than 30 years . This study depend on collect of paraffin embedded PTC biopsies then used Immunohistochemical method to examined the present of TROP2 in all cases.Results: This qualitative study shows significant expression of TROP2 in PTC patients compare with control groups . Conclusion:The current study demonstrate effect of TROP2 expression on PTC development

show abstract

“…Trop2 is a transmembrane glycoprotein that is widely expressed on the surface of a variety of epithelial cell carcinoma cells and rarely expressed or not expressed in normal human tissues [24][25][26]. Our previous research found that Trop2 induced epithelial-mesenchymal transition through mediated β-catenin in gastric cancer [18].…”

Section: Discussionmentioning

confidence: 99%

Trop2 binding IGF2R induces gefitinib resistance in NSCLC by remodeling the tumor microenvironment

Sun¹,

Jia²,

Wang³

et al. 2021

J. Cancer

View full text Add to dashboard Cite

Gefitinib has shown good efficacy in treating recurrent or advanced non-small cell lung cancer (NSCLC), but the drug resistance remains a clinical challenge in medical oncology. In addition, the complex interaction between tumor cells and heterogeneous stromal cells in the adjacent tumor microenvironment (TME) is also an important contributor to drug resistance. So, it is very necessary to detect the related target genes before and after gefitinib treatment dynamically. In this study, the relationship between Trop2 and gefitinib resistance in NSCLC was investigated, and the underlying mechanism was explored. Results showed that Trop2 was associated with EGFR gene mutation and drug resistance in clinical tissues. Trop2 was confirmed to induce gefitinib resistance in NSCLC, and Trop2 binding IGF2R promoted the IGF2-IGF1R-Akt axis to enhance gefitinib resistance and remodeling the TME in NSCLC. Notably, silencing of Trop2 in cancer cells combined with IGF1R inhibitor significantly decreased the proliferation of tumor cells and reshaped the NSCLC TME in vivo and in vitro , including the recruitment of macrophages. These findings deepened the understanding of the function of Trop2 and the involved mechanisms of gefitinib resistance, and may provide new molecular targets for NSCLC with gefitinib resistance.

show abstract

Diagnostic Value of TROP2 Expression in Papillary Thyroid Carcinoma

Cited by 5 publications

References 26 publications

Diagnostic and prognostic utility of TROP-2, SLP-2, and CXCL12 expression in papillary thyroid carcinoma

Diagnostic and prognostic utility of TROP-2, SLP-2, and CXCL12 expression in papillary thyroid carcinoma

The Effect of TROP2 Expression on Papillary Thyroid Carcinoma Development in Iraqi Patients

Trop2 binding IGF2R induces gefitinib resistance in NSCLC by remodeling the tumor microenvironment

Contact Info

Product

Resources

About